Janux Therapeutics, Inc. (JANX) Tops Q2 EPS by 8c

Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q2 EPS of ($0.42), $0.08 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $1.06 million versus the consensus estimate of $875 thousand.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Sharon AI surges premarket; New Oriental gains, Medline slips
• RH (RH) Tops Q1 EPS by 12c